Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$0.66
0.0%
$0.84
$0.63
$3.12
$2.34M1.06207,115 shs63,442 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$2.55
+11.8%
$0.78
$0.44
$2.71
$14.85M0.62.41 million shs4.92 million shs
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
$7.37
$1.60
$6.28
$1.08M0.84180,228 shsN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$7.48
+6.9%
$7.42
$0.06
$0.61
$4.20M2.43802,052 shs4,883 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
+4.88%+1.07%+0.87%-40.34%-70.17%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+42.70%+182.54%+327.97%+325.46%+421.88%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
0.00%0.00%0.00%0.00%0.00%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.00%-11.95%-14.37%+55.04%-79.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
3.026 of 5 stars
3.55.00.00.01.80.01.3
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.4504 of 5 stars
1.50.00.00.01.10.01.3
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
1.7758 of 5 stars
3.03.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
3.00
Buy$14.502,090.33% Upside
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
3.00
Buy$0.85-66.67% Downside
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
0.00
N/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
2.00
Hold$131.251,654.68% Upside

Current Analyst Ratings Breakdown

Latest OHRP, SPRB, NBY, and CANF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2025
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
7/29/2025
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$674K3.48N/AN/A$1.76 per share0.38
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$9.78M1.52N/AN/A$4.25 per share0.60
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/A$3.86 per shareN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$4.91M0.86N/AN/A$1.88 per share3.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
-$13.23MN/A0.00N/AN/AN/A-75.46%-71.18%N/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
-$47.92M-$99.25N/AN/AN/A-555.23%-62.10%-47.49%11/10/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/AN/AN/AN/AN/A
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.15
0.91
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
N/A
3.73
3.73
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
0.01
5.36
5.36

Institutional Ownership

CompanyInstitutional Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
10.70%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
91.71%

Insider Ownership

CompanyInsider Ownership
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
0.10%
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
12.50%
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
83.54 millionN/ANot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
305.82 million4.88 millionNot Optionable
OHR Pharmaceutical Inc stock logo
OHRP
OHR Pharmaceutical
32.83 millionN/ANot Optionable
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
20562,00037.54 millionOptionable

Recent News About These Companies

Spruce Biosciences Announces Reverse Stock Split
SPRB Spruce Biosciences, Inc. - Seeking Alpha
Spruce Biosciences Inc Ordinary Shares
Spruce Biosciences (SPRB) Receives a Hold from RBC Capital
Spruce Biosciences reports delayed annual filing

New MarketBeat Followers Over Time

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$0.66 0.00 (-0.03%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

NovaBay Pharmaceuticals stock logo

NovaBay Pharmaceuticals NYSE:NBY

$2.55 +0.27 (+11.84%)
As of 03:17 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

OHR Pharmaceutical stock logo

OHR Pharmaceutical NASDAQ:OHRP

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Spruce Biosciences stock logo

Spruce Biosciences NASDAQ:SPRB

$7.48 +0.48 (+6.86%)
As of 09/2/2025

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.